NCT05808634View on ClinicalTrials.gov

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

PHASE1RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

September 15, 2028

Study Completion Date

September 15, 2028

Conditions
Advanced Adenocarcinoma
Interventions
DRUG

BA3182

Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM

Trial Locations (9)

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

45219

RECRUITING

The Christ Hospital Cancer Center, Cincinnati

48201

RECRUITING

Karmanos Cancer Institute, Detroit

60611

RECRUITING

Northwestern University, Chicago

60612

RECRUITING

University of Illinois, Chicago

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

92697

RECRUITING

UC Irvine, Irvine

98109

RECRUITING

Fred Hutch Cancer Center, Seattle

06511

RECRUITING

Yale Cancer Center, New Haven

Sponsors

Lead Sponsor

BioAtla, Inc.
All Listed Sponsors
lead

BioAtla, Inc.

INDUSTRY